Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Accumulated Expenses (2016 - 2025)

Syndax Pharmaceuticals has reported Accumulated Expenses over the past 11 years, most recently at $24.4 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $24.4 million for Q4 2025, down 59.48% from a year ago — trailing twelve months through Dec 2025 was $24.4 million (down 59.48% YoY), and the annual figure for FY2025 was $24.4 million, down 59.48%.
  • Accumulated Expenses for Q4 2025 was $24.4 million at Syndax Pharmaceuticals, up from $18.4 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for SNDX hit a ceiling of $60.1 million in Q4 2024 and a floor of $1.9 million in Q1 2022.
  • Median Accumulated Expenses over the past 5 years was $11.6 million (2024), compared with a mean of $17.8 million.
  • Biggest five-year swings in Accumulated Expenses: surged 833.28% in 2021 and later tumbled 83.03% in 2022.
  • Syndax Pharmaceuticals' Accumulated Expenses stood at $4.3 million in 2021, then soared by 459.1% to $24.3 million in 2022, then fell by 10.07% to $21.8 million in 2023, then surged by 175.27% to $60.1 million in 2024, then tumbled by 59.48% to $24.4 million in 2025.
  • The last three reported values for Accumulated Expenses were $24.4 million (Q4 2025), $18.4 million (Q3 2025), and $21.2 million (Q2 2025) per Business Quant data.